MACROSCOPIC INTRAOPERATIVE DIAGNOSIS OF SEROSAL INVASION AND CLINICAL OUTCOME OF GASTRIC-CANCER - RISK OF UNDERESTIMATION

被引:16
作者
ICHIYOSHI, Y
MAEHARA, Y
TOMISAKI, S
OIWA, H
SAKAGUCHI, Y
OHNO, S
SUGIMACHI, K
机构
[1] Department of Surgery Ii, Faculty of Medicine, Kyushu University, Fukuoka
关键词
GASTRIC CANCER; SEROSAL INVASION; INTRAOPERATIVE DIAGNOSIS;
D O I
10.1002/jso.2930590412
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Data on 715 Japanese patients with gastric cancer were studied retrospectively with regard to the relationship between macroscopic and microscopic diagnoses of serosal invasion and clinicopathological factors affecting the accuracy of the macroscopic diagnosis. Although there was no macroscopic evidence of serosal invasion intraoperatively (SO or S1), there was histological evidence of cancer cells on the serosal surface in 69 patients (9.7%). In these serosal invasion-positive cases, the tumors were larger; were located more commonly in the upper third, lesser and greater curvatures of the stomach; were Borrmann type 3 or type 4 tumors, and of an undifferentiated histologic type with an infiltrative growth pattern more commonly, and had more extensive lymphatic and vascular vessel invasion and lymph node metastasis (P < 0.01). Total gastrectomy was done more often for the serosal invasion-positive group, but the extent of lymph node dissection was comparable. Cases of a noncurative resection because of a positive surgical margin were more frequent in the serosal invasion-positive group (8/69 vs. 14/646, P < 0.01), and most had undifferentiated and infiltrative cancers. The 10-year survival rates were 49.2% and 85.5% for patients with and without serosa invasion, respectively. These findings clearly show that the serosal surface, especially in cases of the undifferentiated or infiltrative type of gastric cancer, must be closely inspected intraoperatively. (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:255 / 260
页数:6
相关论文
共 26 条
[1]  
ABE S, 1991, SURGERY, V109, P582
[2]  
[Anonymous], 1981, Jpn J Surg, V11, P140
[3]  
BABA H, 1989, ARCH SURG-CHICAGO, V124, P1061
[4]   GASTROINTESTINAL MALIGNANCY - RATIONALE FOR ADJUVANT THERAPY USING EARLY POSTOPERATIVE INTRAPERITONEAL CHEMOTHERAPY [J].
CUNLIFFE, WJ ;
SUGARBAKER, PH .
BRITISH JOURNAL OF SURGERY, 1989, 76 (10) :1082-1090
[5]   EVALUATION OF THE PROGNOSTIC FACTORS IN GASTRIC-CANCER - THE EFFECT OF CHEMOTHERAPY ON SURVIVAL [J].
CUNNINGHAM, D ;
HOLE, D ;
TAGGART, DJ ;
SOUKOP, M ;
CARTER, DC ;
MCARDLE, CS .
BRITISH JOURNAL OF SURGERY, 1987, 74 (08) :715-720
[6]  
DIXON WJ, 1988, BMDP STATISTICAL SOF, P229
[7]   MITOMYCIN-C AS AN ADJUVANT TREATMENT TO RESECTED GASTRIC-CANCER A 10-YEAR FOLLOW-UP [J].
ESTAPE, J ;
GRAU, JJ ;
LCOBENDAS, F ;
CURTO, J ;
DANIELS, M ;
VINOLAS, N ;
PERA, C .
ANNALS OF SURGERY, 1991, 213 (03) :219-221
[8]  
HARAGUCHI M, 1991, SURG GYNECOL OBSTET, V172, P29
[9]  
HARAGUCHI M, 1987, SURG GYNECOL OBSTET, V164, P335
[10]  
IITSUKA Y, 1979, CANCER, V44, P1476, DOI 10.1002/1097-0142(197910)44:4<1476::AID-CNCR2820440442>3.0.CO